Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

OBJECTIVES: Bedaquiline is the first drug of a new class approved for the treatment of TB in decades. Bedaquiline is metabolized by cytochrome P450 (CYP) 3A4 to a less-active M2 metabolite. Its terminal half-life is extremely long (5–6 months), complicating evaluations of drug–drug interactions. Rif...

Descripción completa

Detalles Bibliográficos
Autores principales: Svensson, Elin M., Murray, Stephen, Karlsson, Mats O., Dooley, Kelly E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356204/
https://www.ncbi.nlm.nih.gov/pubmed/25535219
http://dx.doi.org/10.1093/jac/dku504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356204/
https://www.ncbi.nlm.nih.gov/pubmed/25535219
http://dx.doi.org/10.1093/jac/dku504

Ejemplares similares